TY - DATA T1 - Erratum: Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer PY - 2017/07/25 AU - Igawa S. AU - Sato Y. AU - Ryuge S. AU - Ichinoe M. AU - Katono K. AU - Hiyoshi Y. AU - Otani S. AU - Nagashio R. AU - Nakashima N. AU - Katagiri M. UR - https://karger.figshare.com/articles/dataset/Erratum_Impact_of_PD-L1_Expression_in_Patients_with_Surgically_Resected_Non-Small-Cell_Lung_Cancer/5242108 DO - 10.6084/m9.figshare.5242108.v1 L4 - https://ndownloader.figshare.com/files/8956852 KW - Programmed cell death ligand-1 KW - Squamous non-small-cell lung cancer KW - Prognostic factor N2 - Background: Immunotherapy can become a crucial therapeutic option to improve the prognosis of patients with non-small-cell lung cancer (NSCLC). Here, we evaluated the impact of programmed cell death ligand-1 (PD-L1) expression in surgically resected NSCLCs. Methods: We estimated PD-L1 expression in 229 consecutive NSCLC specimens using rabbit polyclonal antibodies to human PD-L1 in a SP263 immunohistochemical assay and evaluated PD-L1 expression for potential associations with clinicopathological parameters and survival time. Results: PD-L1 expression was significantly higher in tumors from men or current smokers. Squamous cell carcinoma histology was independently associated with high PD-L1 expression according to multivariate analysis (p = 0.015). The 5-year survival rate of patients was 70%, and the difference in the 5-year survival rate according to PD-L1 expression was not statistically significant (high expression group [67%] vs. low expression group [68%]); however, the squamous cell carcinoma group exhibited significantly lower 5-year survival rates as compared to the non-squamous cell carcinoma group (53 and 71%, respectively; p = 0.026). Conclusion: Here, we revealed high PD-L1 expression and poor prognosis observed in patients with surgically resected squamous NSCLC as compared with non-squamous NSCLC. Our results support the identification of patient subsets that most likely respond to anti-PD-1 therapy as the first step in precision medicine. ER -